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Abstract
Matrix metalloproteinase-2 (MMP-2) has been suggested to play a crucial role in tumor invasion and angiogenesis. In
order to understand the mechanisms underlying proMMP-2 activation, we compared the biochemical and cellular events
triggered by two potent MMP-2 activators, the lectin concanavalin A (ConA) and the cytoskeleton disrupting agent
cytochalasin D (CytoD). Incubation of U87 human glioma cells for 24 h in the presence of ConA or CytoD induced a
marked activation of proMMP-2 and this activation was correlated in both cases with an increase in the mRNA levels of
MT1-MMP. At the protein level, proMMP-2 activation induced by CytoD or ConA strongly correlated with the appearance
of a 43-kDa MT1-MMP proteolytic breakdown product in cell lysates. Interestingly, CytoD also induced a very rapid (2 h)
activation of proMMP-2 that was independent of protein synthesis. Under these conditions, CytoD also promoted the rapid
proteolytic breakdown of the 63 kDa pro form of MT1-MMP, resulting in the appearance of the 43 kDa MT1-MMP
processed form. Overexpression of a recombinant full-length MT1-MMP protein in glioma cells resulted in the activation of
proMMP-2 that was correlated with the generation of the 43 kDa fragment of the protein. By contrast, overexpression of the
protein in COS-7 cells promoted proMMP-2 activation without inducing the production of the 43 kDa fragment. These
results thus suggest that activation of proMMP-2 occurs through both translational and post-translational mechanisms, both
involving proteolytic processing of membrane-associated MT1-MMP. This processing of MT1-MMP is, however, not
essential to proMMP-2 activation but may represent a regulatory mechanism to control the activity of MT1-MMP. ß 2000
Elsevier Science B.V. All rights reserved.
1. Introduction
Matrix metalloproteinases (MMPs) represent a
growing family of zinc-dependent proteases involved
in matrix turnover occurring during normal and
pathological processes [1]. MMPs are secreted by
cells as proenzymes that must be cleaved in order
to become functional. This latency of the MMP zy-
mogens is due to the presence of the N-terminal pro
domain that shields the catalytic cleft through coor-
dination of the catalytic zinc molecule [2]. Cleavage
of the pro domains of MMPs is mediated in most
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cases by soluble MMPs or by proteases of the serine
families such as plasmin, plasma kalleikrin and neu-
trophil elastase [1,3]. By contrast to most MMPs,
proMMP-2 possesses a propeptide that is not suscep-
tible to proteolytic cleavage by serine proteinases [4]
and recent evidence have suggested that its activation
is distinct and involves another member of the MMP
family, the MT1-MMP [5]. MT-MMPs are unique
among the members of the MMP family in that
they contain a transmembrane domain that allows
their localization to the cell surface [5,6]. Five mem-
bers of this family have been described to date but
most of the knowledge of this subclass has been ob-
tained from the study of MT1-MMP function [5,7^
9]. This protein acts as a membrane receptor for
proMMP-2, a binding that requires TIMP-2 [7].
Cross-linking and binding experiments have revealed
that the N-terminal domain of TIMP-2 binds with
high a⁄nity to the catalytic domain of MT1-MMP,
followed by the binding of the C-terminal domain of
proMMP-2 to the C-terminal domain of TIMP-2,
resulting in the formation of a trimolecular complex
[7,8]. This results in the processing of proMMP-2 by
cleavage of the propeptide region of the enzyme by
an adjacent MT1-MMP, followed by autoproteolysis
to generate the fully active enzyme [2,9].
Since MMP-2 is constitutively secreted by many
cancer cells, expression of MT1-MMP at the cell sur-
face may thus represent a key regulatory step for
MMP-2 activation and tumor invasion [5]. For this
reason, many studies have focused on the pathways
that are involved in the expression of MT1-MMP.
Numerous studies have shown that agents that pro-
mote proMMP-2 activation such as the lectin conca-
navalin A [10], phorbol esters [11] or the cytoskeleton
disrupting agent cytochalasin D [12,13], induce a
concomitant increase in MT1-MMP mRNA, sug-
gesting that this upregulation is necessary for
proMMP-2 activation. However, the increase in
MT1-MMP observed at the mRNA level is not al-
ways correlated with the presence of the protein in
cell lysates and, in many cases, cells expressing high
levels of MT1-MMP do not show any detectable
proMMP-2 activation [14]. At the protein level, the
strongest correlation existing between MT1-MMP
and proMMP-2 activation is the presence of an im-
munoreactive 43 kDa protein that reacts with anti-
MT1-MMP antibodies [15^18]. This intermediate
represents a truncated form of the protein cleaved
within the catalytic site and that is presumably de-
void of enzymatic activity [16]. It is, however, not
clear how this fragment is involved in the
proMMP-2 activation process and in the overall mo-
lecular events linking MT1-MMP processing to
proMMP-2 activation.
In this study, we have compared the activation of
proMMP-2 induced by two di¡erent agents, the lec-
tin concanavalin A (ConA) and the cytoskeleton dis-
rupting agent cytochalasin D (CytoD), and examined
the e¡ect of these agents on the expression and pro-
cessing of the MT1-MMP protein. We show that in a
glioma cell line, CytoD rapidly induces activation of
proMMP-2 in a protein synthesis-independent man-
ner and that this activation involves the processing of
MT1-MMP from its 63 kDa pro form to a 43 kDa
fragment. This processing of the protein is however
not essential to proMMP-2 activation but may rep-
resent a regulatory mechanism to control the activity
of MT1-MMP. These results suggest that changes of
the actin cytoskeleton structure of cancer cells may
represent a rapid stimulus triggering the degradation
of extracellular matrix proteins by MMP-2.
2. Material and methods
2.1. Materials
The human glioblastoma cell line U87 and COS-7
cells were purchased from the American Tissue Cul-
ture Collection and were maintained in modi¢ed Ea-
gle’s medium (MEM) containing 10% fetal bovine
serum (HyClone Laboratories), 100 units/ml penicil-
lin and 100 Wg/ml streptomycin. Concanavalin A,
cytochalasin D and APMA were purchased from
Sigma. The inhibitors of signal transduction tested
in this study were provided by BioMol. The anti-
MT1-MMP polyclonal antibodies (raised against
the hinge region) and monoclonal antibodies against
human MMP-2 and TIMP-2 were from Chemicon.
The TriZOL reagent was from Gibco and the Titan
one-tube RT^PCR kit was from Roche Molecular
Biochemicals. Reagents for electrophoresis were pur-
chased from BioRad.
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2.2. Activation of proMMP-2
For experimental purposes, cells were plated in
Nunc 33-mm 6-well plastic dishes at 105 cells/dish,
and grown in a humidi¢ed atmosphere containing
5% CO2 and 90% air at 37‡C. The extent of
proMMP-2 activation was evaluated by the appear-
ance of a 62 kDa gelatinolytic band on gelatin zymo-
grams following stimulation of the cells. Brie£y, 80%
con£uent U87 cells were serum-starved by overnight
incubation in serum-free MEM. Under these condi-
tions, the conditioned media contained large
amounts of proMMP-2 with no detectable levels
of active enzyme. To induce activation, ConA (10
Wg/ml) or CytoD (1 WM) were added to the condi-
tioned media and the cells were further incubated for
di¡erent periods of time. For the inhibition studies,
the cells were preincubated for 1 h in the presence of
the tested inhibitors prior to the addition of CytoD
or ConA.
Gelatin zymography was performed with a Mini-
Protean II apparatus according to standard proce-
dures. Brie£y, the samples (20 Wl of conditioned me-
dium) were suspended in a bu¡er containing 62.5
mM Tris^HCl (pH 6.8), 10% glycerol, 2% sodium
dodecyl sulfate (SDS) and 0.00625% bromophenol
blue and loaded without heating on a 9% SDS^poly-
acrylamide gel containing 0.1% gelatin. Electropho-
resis (SDS^PAGE) was carried out at a constant
voltage of 100 V. After electrophoresis, the gels
were soaked in 2.5% Triton X-100 (2U30 min) at
room temperature and rinsed ¢ve times in Nanopure
water. The gels were incubated 20 h at 37‡C in a
bu¡er containing 50 mM Tris^HCl (pH 7.6),
20 mM NaCl, 5 mM CaCl2 and 0.02% Brij-58. The
gels were then stained in 0.1% (w/v) Coomassie blue
R-250 in 30% methanol and 10% acetic acid, and
destained in the same solution without the dye.
2.3. Isolation of cell lysates and crude membrane
fractions
Cells were grown in 75-cm2 £asks to 80% con£u-
ence, serum-starved overnight and incubated in the
absence or in the presence of CytoD or ConA as
described above. After removal of the conditioned
media, cells were washed two times in phosphate-
bu¡ered saline and collected by scraping. For the
preparation of whole cell lysates, cells were resus-
pended in a bu¡er containing 1% Triton X-100,
0.5% Nonidet P-40, 150 mM NaCl and 20 mM
Tris-HCl (pH 7.4). The mixture was incubated on
ice for 1 h and insoluble matter was removed by
centrifugation. For the isolation of crude membrane
fractions, the suspended cells were homogenized us-
ing a Polytron instrument (3U20-s bursts at 50%
maximal power), centrifuged at low speed to remove
cell debris and unbroken cells, and ultracentrifuged
to collect the particulate fraction. The resulting mem-
branes were resuspended in 20 mM Tris^HCl (pH
7.4) and stored at 380‡C until use.
2.4. Immunoblotting procedures
Equal amounts of proteins from control and
treated cells were resuspended in sample bu¡er and
separated by SDS^PAGE, using 9% acrylamide gels.
After electrophoresis, proteins were electrotrans-
ferred to a 0.45-Wm pore size polyvinylidene di£uo-
ride (PVDF) membrane using a Milliblot graphite
electroblotter (Millipore) in the presence of a transfer
bu¡er containing 96 mM glycine, 10 mM Tris^HCl
and 10% methanol. Hydrophobic or non-speci¢c
sites were blocked overnight at 4‡C with 5% non-
fat dry milk in Tris-bu¡ered saline (150 mM Tris,
20 mM Tris^HCl, pH 7.5) containing 0.3% Tween-
20 (TBST). Membranes were washed three times in
TBST and incubated with the primary antibodies
(1/1000 dilution) in TBST containing 3% bovine se-
rum albumin and 0.02% sodium azide, followed by a
1-h incubation at room temperature with horseradish
peroxidase-conjugated anti-rabbit IgG (1/10000 dilu-
tion) or anti-mouse (1/2500 dilution) in TBST con-
taining 5% non-fat dry milk. PVDF membranes were
washed three times in TBST and immunoreactive
material was visualized by enhanced chemilumines-
cence (ECL, Amersham-Pharmacia Biotech).
2.5. Total RNA isolation and RT^PCR analysis
Total RNA was extracted from cultured U87 cells
using the TriZOL Reagent (Life Technologies) a
mono-phasic solution of phenol and guanidine iso-
thiocyanate. RNA was quanti¢ed using absorbance
at 260 nm and subjected to RT^PCR using the Titan
One Tube RT^PCR kit (Roche Molecular Biochem-
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icals). Primers used for the PCR reactions were cus-
tom synthesized (Sheldon Biotechnology Centre,
Montreal, Quebec, Canada) and were all derived
from human sequences [13]. MMP-2 and MT1-
MMP primers respectively amplify a 227 bp and a
182 bp fragment. The human L-actin primers (Boehr-
inger Mannheim), that amplify a 587 bp fragment
from reverse-transcribed preparations, were used as
the standard. Typically, ¢rst strand cDNA was syn-
thesized by RT using 1 Wg of total RNA, 5 units of
RNase Inhibitor and 1 Wl of Titan Enzyme Mix
(AMV and Expand High Fidelity) which were added
to a 50-Wl reaction mixture containing 1.5 mM
MgCl2, 5 mM DTT, dNTP (0.2 mM each), and
primers (0.4 WM each). Samples were placed for
20 min in a Perkin^Elmer GeneAmp 9700 thermo-
cycler equilibrated at 60‡C. The RT^PCR mixture
was then heated to 94‡C for 5 min and run for 25
(L-actin) or 30 (MMP-2 and MT1-MMP) cycles at
94‡C for 30 s, 55‡C for 1 min and 72‡C for 1 min,
followed by 10 min elongation at 72‡C. Under these
conditions, the three gene products were found to be
at the exponential phase of the ampli¢cation [13].
PCR products were resolved on 2% agarose gels con-
taining 1 Wg/ml ethidium bromide.
2.6. Cloning and transfection of MT1-MMP
The cDNA encoding MT1-MMP was isolated by
nested PCR using total cellular RNA extracted from
U-87 glioblastoma cells as the template. The ¢rst
ampli¢cation was performed for 30 cycles at 55‡C
using the oligonucleotide primers derived from
nucleotides 40 to 64 (5P-TGGCGGTGCGACCC-
CAGGGCGTGGG-3P, sense) and 1937 to 1913 (5P-
ACCCACCACCACCTGCTGCCACTGG-3P, anti-
sense) of the human MT1-MMP cDNA (GenBank
accession number D26512). The resulting 1.9 kb
cDNA fragment was reampli¢ed with the oligonu-
cleotides (5P-CAGCTGCAGGAATTCGTGGTCT-
CGGACCATGTCTCCCG-3P, sense) and (5P-CA-
GCTGCAGATGGGCGTCAGACCTTGTCCAGC-
3P, antisense) for 40 cycles at 60‡C, and the resulting
1.4 kb cDNA was subcloned into pCR-2.1 vector
using the TOPO-TA cloning kit (Invitrogen). The
HindIII and XbaI restriction sites present in the
pCR-2.1 vector were used for subcloning into a
pcDNA (3.1+) expression vector (Invitrogen). Cells
were transiently transfected with the resulting plas-
mids using the non-liposomal formulation FU-
GENE-6 transfection reagent (Roche Molecular Bio-
chemicals) and cell lysates were prepared 36 h post-
transfection. Mock transfections of cultures with the
pcDNA (3.1+) expression vector alone were used as
controls.
3. Results
3.1. Activation of proMMP-2 by human glioblastoma
cells
The U87 human glioblastoma cell line constitu-
tively secretes large amounts of proMMP-2 into the
conditioned medium and was used as a model for the
study of proMMP-2 activation. We ¢rst examined
the potential activation of this process by a variety
of agents or culture conditions that have been used
to activate proMMP-2 in other cell systems. As
shown in Fig. 1A, the addition of the lectin ConA
promoted a strong activation of proMMP-2, as re-
£ected by the appearance of a 62 kDa band in gelatin
zymograms. A similar activation was observed after
treatment of the cells with CytoD, a well-character-
ized cytoskeleton-disrupting agent (Fig. 1A). The ef-
fect of CytoD was not related to a non-speci¢c e¡ect
of the agent on cell shape since colchicine, a micro-
tubule destabilizing drug that also induce cell round-
ing, had no e¡ect on proMMP-2 activation. Other
agents reported to promote activation of proMMP-2
such as PMA [11], elastin [19], and orthovanadate
[20] were also examined but failed to induce
proMMP-2 activation at all tested concentrations.
Cells grown on ¢bronectin-coated dishes [17] also
failed to promote detectable activation of
proMMP-2. Based on these results, the activation
of proMMP-2 induced by ConA and CytoD was
further investigated in this cell line.
We ¢rst compared the kinetics of proMMP-2 acti-
vation induced by ConA and CytoD (Fig. 1B). In
order to visualize the activation of proMMP-2 at
short incubation times, the cells were serum-starved
overnight to allow the production of proMMP-2 in
the conditioned medium, after which CytoD and
ConA were added. Under these conditions, we ob-
served that addition of CytoD (1 WM) rapidly in-
BBAMCR 14657 11-9-00
D. Gingras et al. / Biochimica et Biophysica Acta 1497 (2000) 341^350344
duced the activation of proMMP-2, the active 62 kDa
form of the protein being detected as early as 1 h
after CytoD addition. This response of U87 cells to
CytoD was distinct from that to ConA since activa-
tion of proMMP-2 under these conditions required
at least 8 h of treatment.
We next examined the e¡ect of a wide variety of
inhibitors of signal transduction pathways on the
rapid induction of proMMP-2 activation by CytoD.
The tested inhibitors included inhibitors of protein
kinases A (H-89), C (calphostin C, and GF109203)
and tyrosine kinases (genistein), inhibitors of intra-
cellular signaling intermediates such as the mitogen-
activated protein kinase (PD98052), phospholipase C
(U73122), phosphatidylinositol 3-kinase (LY294002),
and also inhibitors of calcium channels (thapsigar-
gin), myosin phosphatase (tautomycin) and protein
synthesis (cycloheximide). Cells were serum-starved
for 18 h and preincubated for 1 h with the indicated
inhibitors prior to the addition of 1 WM of CytoD for
2 h. As shown in Fig. 1C, incubation of cells in the
presence of CytoD for 2 h resulted in a detectable
activation of proMMP-2 that was insensitive to all
tested inhibitors. These results suggest that the rapid
activation of proMMP-2 by CytoD occurs through a
posttranslational mechanism that does not involve
the activation of well-characterized signaling cas-
cades.
Fig. 1. proMMP-2 activation to the 62 kDa form occurs upon
incubation of U87 glioma cells with ConA and CytoD. (A) Ef-
fect of various agents or culture conditions on the activation of
proMMP-2 by U87 cells. U87 cells (80% con£uent) were se-
rum-starved for 18 h, followed by a 24-h incubation in the
absence (lane 1) or in the presence of the following agents:
10 Wg/ml concanavalin A (lane 2), 1 WM cytochalasin D (lane
3), 5 WM colchicine (lane 4), 100 nM PMA (lane 5), 100 WM
orthovanadate (lane 6), 50 Wg/ml elastin (lane 7). In lane 8, cells
were seeded on a ¢bronectin matrix and serum-starved as de-
scribed above. Conditioned media were collected, centrifuged to
eliminate cell debris and 20 Wl of the resulting media were sub-
jected to gelatin zymography. The electrophoretic migration of
APMA-activated MMP-2 is shown on the right. (B) Time
course of proMMP-2 activation induced by ConA and cytocha-
lasin D in U87 cells. Cells were serum-starved as described in
A. after which 1 WM CytoD (upper panel) or 10 Wg/ml of
ConA (lower panel) were added. The cells were incubated for
the indicated times and the extent of proMMP-2 activation was
monitored by gelatin zymography. (C) Inhibition of the rapid
CytoD-induced activation of proMMP-2. Cells were starved in
serum-free medium for 18 h and then preincubated for 2 h in
the absence (lanes 1 and 2) or in the presence of the following
inhibitors : 100 nM calphostin C (lane 3), 100 nM H-89 (lane
4), 50 WM genistein (lane 5), 5 WM GF109203 (lane 6), 10 WM
PD98059 (lane 7), 10 WM U73122 (lane 8), 10 WM LY294002
(lane 9), 10 nM tautomycin (lane 10), 30 nM thapsigargin (lane
11) and 5 Wg/ml cycloheximide (lane 12). The extent of
proMMP-2 activation induced by 2 h incubation with 1 WM
CytoD was monitored as described above. Lane 1 represents
conditioned media from unstimulated cells.
Fig. 2. RT^PCR analysis of MT1-MMP and MMP-2 mRNA
levels following treatment of U87 cells with ConA or CytoD.
Total RNA was extracted from U87 glioblastoma cells either
untreated (lanes 1) or treated for 24 h with ConA (lanes 2), 2 h
with cytochalasin D (lanes 3) or 24 h with cytochalasin D
(lanes 4) and subjected to RT^PCR using primers speci¢c for
MT1-MMP, MMP-2 or L-actin as a control. The resulting
PCR products (10 Wl) were resolved on 2% agarose gels con-
taining 1 Wg/ml ethidium bromide. Lanes 5 represent control re-
actions in which reverse transcriptase was omitted.
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Numerous studies have suggested that both ConA-
and CytoD-induced activation of proMMP-2 occur
through an upregulation of the MT1-MMP mRNA
levels [10,12,13]. We thus examined if a similar mech-
anism was involved in the activation of proMMP-2
in U87 cells. Total RNA was isolated from cells
treated either for 2 h or 24 h with CytoD and for
24 h with ConA, and RT^PCR was performed using
speci¢c sense and anti-sense primers for MT1-MMP,
MMP-2, or L-actin as a control. As shown in Fig. 2,
treatment of the cells for 2 h with CytoD had no
e¡ect on either MT1-MMP or MMP-2 mRNA lev-
els. By contrast, 24-h incubation with CytoD or
ConA induced a 2-fold increase in the mRNA levels
of these proteins whereas the levels of L-actin were
unchanged. These results suggest that the activation
of proMMP-2 induced by 24 h incubation with Cy-
toD and ConA is related to an upregulation of the
MT1-MMP levels. However, these results support
the notion that the rapid activation of proMMP-2
induced by 2 h incubation with CytoD does not in-
volve an increase in the synthesis of the MT1-MMP
protein.
3.2. Activation of proMMP-2 by glioma cells is
correlated with the processing of MT1-MMP to a
43 kDa fragment
We next examined whether the increase in the
mRNA levels of MT1-MMP was correlated with a
similar increase in its protein levels within the cells.
Immunoblotting of the control cell lysate detects a 55
kDa form of the MT1-MMP protein, reported to
represent the active form of the enzyme (Fig. 3). In-
cubation of the cells with either ConA or CytoD
induced a major activation of proMMP-2 but did
not promote a signi¢cant increase in the amount of
this protein, rather inducing the appearance of the
MT1-MMP 43 kDa inactive form (p43) (Fig. 3A).
Interestingly, the presence of the MT1-MMP 43
kDa (p43) inactive form is strongly correlated with
the extent of proMMP-2 activation. For example,
addition of increasing concentrations of ConA re-
sulted in the gradual appearance of this protein
that was concomitant with the presence of the active
form of MMP-2 (62 kDa) in the conditioned medium
(Fig. 3B). In fact, we observed throughout this study
that the extent of proMMP-2 activation by glioma
Fig. 3. Immunodetection of MT1-MMP in U87 cell lysates fol-
lowing stimulation with ConA and Cyto D. (A) Cells were in-
cubated for 24 h in the presence of 10 Wg/ml of ConA or 1 WM
Cyto D and proMMP-2 activation in the CM was monitored
by gelatin zymography while the processing of MT1-MMP in
the corresponding cell lysates was analyzed by immunoblotting
with anti-MT1-MMP polyclonal antibodies. (B) Conditioned
media (upper panel) and whole cell lysates (lower panel) were
isolated from cells stimulated with the indicated concentrations
of ConA, as described in Section 2. The extent of proMMP-2
activation was examined by immunoblotting of the CM with an
anti-MMP-2 monoclonal antibody and the presence of MT1-
MMP in the corresponding cell lysates was examined by immu-
noblotting with polyclonal antibodies raised against the hinge
region of the human MT1-MMP protein. (C) Zymograms and
corresponding cell lysates obtained throughout this study
(n = 46) were scanned by laser densitometry. proMMP-2 activa-
tion was quanti¢ed as the ratio of the active to the inactive
form whereas processing of MT1-MMP was expressed as the
ratio of the 43 kDa form to the 55 kDa form.
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cells was always correlated with the presence of the
p43 proteolytic fragment of MT1-MMP. A large
number of zymograms with various levels of acti-
vated MMP-2 were analyzed as a function of the
levels of the MT1-MMP 43 kDa fragment in the
corresponding lysates. To allow comparison of data
from one experiment to another, we expressed the
activation of proMMP-2 as the ratio of active/pro
forms, whereas the levels of p43 were expressed as
the ratio of p43/p55. As shown in Fig. 3C, we ob-
served a very strong correlation between p43 levels
and the extent of proMMP-2 activation.
We next examine whether the rapid (2 h) activa-
tion of proMMP-2 by CytoD also involves the pro-
cessing of MT1-MMP to the 43 kDa form. Under
these short incubation times, however, p43 was
barely detectable in the crude cell lysates, possibly
due to the lack of e¡ect of CytoD on MT1-MMP
synthesis. In order to better visualize the e¡ects of
CytoD on MT1-MMP expression and processing, we
thus isolated crude membranes from cells treated
with these agents and the presence of MT1-MMP
was evaluated by immunoblotting.
Using this approach, we observed that membranes
isolated from control cells contain the 63 kDa pro
form of MT1-MMP (p63), in addition to the pre-
dominant 55 kDa form (p55) of the protein detected
in crude lysates (Fig. 4). The incubation of the cells
with CytoD for 2 h resulted in the complete disap-
pearance of p63 and the appearance of the p43
breakdown product. After 24 h incubation with Cy-
toD, p63 returned to its initial levels, while the levels
of p55 and p43 remained largely unchanged. A sim-
ilar pro¢le is observed following a 24 h treatment
with ConA. Interestingly, reprobing of the blot
with an anti-MMP-2 monoclonal antibody showed
the presence of an active membrane-associated
form of proMMP-2 which correlated with the ap-
Fig. 5. Proteolytic cleavage of MT1-MMP to its 43 kDa frag-
ment is not essential for proMMP-2 activation. (A) COS-7 and
U87 cells were transfected with vector alone or containing the
MT1-MMP cDNA as described in Section 2. Cells were subse-
quently washed and incubated for 18 h in CM isolated from
U-87 cells and containing high levels of secreted proMMP-2.
The activation of proMMP-2 was monitored by gelatin zymog-
raphy as described in the legend to Fig. 1. (B) Lysates (20 Wg
of protein) isolated from mock and MT1-MMP-transfected
COS-7 and U87 cells were separated on a 9% SDS^PAGE and
immunoblotted using anti-MT1-MMP antibodies. The 63 and
60 kDa bands represent the unprocessed and processed active
forms of MT1-MMP, respectively, whereas the 43 kDa band is
the processed inactive form.
Fig. 4. Rapid activation of proMMP-2 is correlated with the
processing of MT1-MMP at the cell membrane. U87 cells were
treated with Cyto D or ConA as described in the legend to
Fig. 1. After collecting the CM, cells were washed, homoge-
nized and used for the isolation of a crude membrane fraction.
Equal amounts of membrane proteins (10 Wg per lane) were re-
solved on a 9% acrylamide gel and electrotransferred to PVDF
membranes. The resulting membranes were immunoblotted with
either anti-MT1-MMP polyclonal antibodies (upper panel), with
an anti-MMP-2 monoclonal antibody (middle panel) or with an
anti-TIMP-2 monoclonal antibody (lower panel).
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pearance of the 43 kDa form of MT1-MMP. The
amount of membrane-associated TIMP-2 were not,
however, altered by these treatments. These results
indicate that CytoD rapidly induces activation of
proMMP-2 and that this process occurs concomi-
tantly with the processing of MT1-MMP to its
43 kDa form.
3.3. Processing of MT1-MMP to the 43 kDa form is
not essential for proMMP-2 activation
To investigate whether the processing of MT1-
MMP to its 43 kDa fragment represents an essential
step in proMMP-2 activation, we examined the e¡ect
of overexpressed MT1-MMP in U87 and COS-7
cells. As shown in Fig. 5, the full-length protein over-
expressed in both cell lines promote a signi¢cant in-
crease in proMMP-2 activation. However, immuno-
blotting of the corresponding cell lysates with anti-
MT1-MMP antibodies showed very distinct process-
ing of the protein under these conditions. In COS-7
cells, the recombinant protein migrated at its pre-
dicted molecular mass value of 63 kDa but the pro-
tein was not processed to neither the 55 or the 43
kDa fragments. By contrast, small amounts of the
protein overexpressed in U87 cells remained in the
63 kDa form, the majority of the protein being pro-
cessed to the 55 and 43 kDa forms. These results
thus suggest that signi¢cant di¡erences in MT1-
MMP processing occurs during the activation of
proMMP-2 by di¡erent cell types and that the deg-
radation of MT1-MMP to the 43 kDa fragment is
not essential to proMMP-2 activation.
4. Discussion
Activation of proMMP-2 by MT1-MMP located
at the tumor cell surface is thought to represent a
crucial step in tumor invasion and metastasis [21].
In gliomas, particularly, the activation of proMMP-
2 has been strongly correlated with their invasive
potential [22] and MT1-MMP has been suggested
to play an important role in glioma invasiveness
[23]. These considerations led us to investigate the
factors leading to proMMP-2 activation by glioma
cells as well as the involvement of the MT1-MMP
protein in this process.
As reported for many cell types, the plant lectin
ConA and the cytoskeleton disrupting agent CytoD
were found to induce a dramatic increase in the ac-
tivation of proMMP-2 by the glioma cells. The ob-
served increase in proMMP-2 activation induced by
prolonged incubation of the cells with these two
agents was correlated with an upregulation of the
MT1-MMP mRNA levels suggesting that it occurs
through translational/transcriptional pathways.
However, by contrast to ConA, CytoD was found
to rapidly induce proMMP-2 activation, its e¡ects
being detectable as early as 1 h after the addition
of the toxin. To our knowledge, this represents the
fastest induction of proMMP-2 activation reported
to date. For example, 48 h incubation with orthova-
nadate and 72 h incubation with L-amyloid peptide
was required to observe a similar activation of
proMMP-2 [20,24]. Moreover, this rapid activation
was insensitive to a protein synthesis inhibitor and
was not associated with an increase in MT1-MMP
mRNA levels, suggesting that it occurs through the
activation of a posttranslational mechanism.
At the protein level, treatment of the cells for 2 h
with CytoD induced the disappearance of the pro
form of MT1-MMP (63 kDa) and the concomitant
appearance of the 43 kDa fragment, with no signi¢-
cant changes in the levels of the 55 kDa form. This
proteolytic processing of MT1-MMP is correlated
with the activation of membrane-associated
proMMP-2. The observation that incubation of
U87 cells for 2 h with CytoD is su⁄cient to induce
the processing of MT1-MMP to its 43 kDa fragment
and that under these conditions no 63 kDa is
present, clearly indicates that this step is strongly
associated with proMMP-2 activation in the absence
of protein synthesis. Upon prolonged incubation
with either ConA or CytoD, the levels of the
63 kDa form returned to their initial values, while
the levels of the 55 and 43 kDa proteins moderately
increased. This suggests that the 63 kDa pro form of
MT1-MMP is synthesized (from the increased MT1-
MMP mRNA levels) but is continuously processed
to the 55 and 43 kDa fragments.
We next evaluated whether this proteolytic pro-
cessing is essential to proMMP-2 activation, using
a recombinant form of MT1-MMP expressed in a
homologous (U87) or heterologous (COS-7) cell sys-
tem. Interestingly, we observed that transfection of
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the protein induced proMMP-2 activation in both
cell lines but that the overexpressed protein was dif-
ferentially processed in these cells. In COS-7 cells,
MT1-MMP was expressed as a 63 kDa protein
with no detectable levels of processed forms. By con-
trast, overexpression of the protein in U87 cells re-
sulted in moderate amounts of p63 while p55 and
p43 increased. These results thus suggest that the
pro form of MT1-MMP has the intrinsic ability to
induce proMMP-2 activation, as reported recently
[25] and that the proteolytic processing of the protein
does not participate in this process. Moreover, these
results also suggest that active MMP-2 is not respon-
sible for the cleavage of MT1-MMP to its 43 kDa
fragment since this cleavage is not observed in
COS-7 cells despite equivalent amounts of active
MMP-2.
The nature of the MT1-MMP species responsible
for the activation of proMMP-2 remains controver-
sial. By analogy to other members of the MMP fam-
ily, it is postulated that the active form of the pro-
tein, lacking the pro domain (55 kDa species) is
responsible for the activation of proMMP-2. In this
respect, co-expression of MT1-MMP and TIMP-2 in
kidney epithelial cells resulted in the binding of
TIMP-2 to the active form of MT1-MMP and sub-
sequent activation of proMMP-2 [26]. By contrast,
another study reported that the 63 kDa pro form of
MT1-MMP was essential for the binding of TIMP-2
and proMMP-2 at the cell surface, also resulting in
proMMP-2 activation [25]. However, a soluble form
of MT1-MMP lacking the pro domain (55 kDa
MT1-MMP) was found to be able to activate
proMMP-2 [25]. This suggests that two distinct pop-
ulations of MT1-MMP may be needed for e⁄cient
proMMP-2 activation: an intact 63 kDa form that is
involved in the formation of the trimolecular com-
plex and a 55 kDa form that would be responsible
for the catalytic cleavage of proMMP-2, and possibly
for the cleavage of MT1-MMP itself to generate the
43 kDa fragment. Whether these di¡erences in the
proposed mechanisms involved in the MT1-MMP-
dependent activation of proMMP-2 are related to
di¡erent experimental approaches or to the complex
interplay between the levels of MT1-MMP, TIMP-2
and proMMP-2 in di¡erent cell systems remain to be
established. However, our results suggest that at least
some of these discrepancies may arise from the use of
transfected cells overexpressing MT1-MMP com-
pared to native cell systems.
In summary, we show for the ¢rst time that tumor
cells can promote a rapid and signi¢cant activation
of proMMP-2 upon changes in the arrangement of
their cellular actin cytoskeleton. Importantly, a sig-
ni¢cant proportion of proMMP-2 was activated at
the cell surface and remained associated with the
membrane and may thus contribute very actively to
tumor invasion [27]. This rapid activation of
proMMP-2 is performed through the activation of
an endogenous pool of MT1-MMP already located
at the cell membrane. Such a transcription-independ-
ent mechanism is associated with the consumption of
the 63 kDa form of MT1-MMP and the concomitant
appearance of the 43 kDa fragment. This is followed
by an increase in the MT1-MMP mRNA levels, re-
sulting in the reappearance of the 63 kDa protein at
the cell surface, allowing sustained activation of
proMMP-2 despite continuous proteolytic processing
of MT1-MMP. Since this processing does not appear
to be essential for activity, it may serve as a negative
autoregulatory mechanism to control the amount of
active MT1-MMP at the cell surface. The elucidation
of the cytoskeleton-dependent pathways that pro-
mote proMMP-2 activation and the concomitant
MT1-MMP processing will thus be of considerable
interest for our understanding of the mechanisms
underlying activation of proMMP-2 by MT1-MMP.
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